Source comparison
Melanotan-1 for Tanning: Peptide Comparison
Choosing the right melanocortin agonist depends on receptor specificity, side effect profile, and intended experimental endpoint. The table below compares Melanotan-1, Melanotan-2, and endogenous α-MSH across key pharmacological parameters. Melanotan-1 Selecti
This comparison does not assign a generated winner or score.
- Choosing the right melanocortin agonist depends on receptor specificity, side effect profile, and intended experimental endpoint. The table below compares Melanotan-1, Melanotan-2, and endogenous α-MSH across key pharmacological parameters.
- Melanotan-1
- Selective MC1R agonist
- ~30 minutes (plasma), 4–6 hours (tissue)
- Minimal; mild nausea in <10% at high doses
- Photoprotection studies, photosensitivity disorder models, melanogenesis research
- Best option for pigmentation research with minimal off-target effects. FDA-approved as afamelanotide (Scenesse) for erythropoietic protoporphyria. Selective MC1R affinity eliminates CNS and GI side effects seen with Melanotan-2.
- Melanotan-2
- Non-selective (MC1R, MC3R, MC4R, MC5R)
- ~33 minutes (plasma), 6–8 hours (tissue)
- Nausea (89%), facial flushing (78%), spontaneous erections (64% in males), appetite suppression
- Appetite modulation studies, sexual dysfunction models, broad melanocortin pathway research
- Higher side effect burden due to MC4R agonism. Useful for multi-receptor melanocortin research but not suitable for isolated pigmentation studies. Off-target CNS effects confound photoprotection endpoints.
- α-MSH (endogenous)
- Broad melanocortin affinity (MC1R, MC3R, MC4R, MC5R)
- ~5 minutes (rapid enzymatic degradation)
- None (endogenous hormone at physiological levels)
- Baseline melanocortin pathway characterization, control comparisons
- Rapid degradation limits experimental utility. Cleaved by neprilysin and other peptidases within minutes of administration. Not viable for sustained pigmentation induction.
- Melanotan-1 is the preferred analog for photoprotection and melanogenesis research due to its selective MC1R affinity and favorable safety profile. The FDA's approval of afamelanotide under the trade name Scenesse in 2019 validates its clinical utility for patients with erythropoietic protoporphyria. A rare photosensitivity disorder where UV exposure causes acute phototoxic pain. Clinical trials demonstrated that afamelanotide pretreatment increased pain-free sun exposure by 69% compared to placebo, with pigmentation appearing within one week and persisting for 4–8 weeks post-treatment. No other melanocortin agonist has achieved FDA approval for photoprotection, making Melanotan-1 the gold standard for research models investigating UV tolerance and melanin-mediated ROS scavenging.